11/4/2025

Janusmed sex and gender

Janusmed sex and gender – Lecanemab

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
B B
B B

Lecanemab

Lecanemab

Class : B

Show all info

Print

Contact us

  1. Nationella riktlinjer – Utvärdering 2018 Vård och omsorg vid demenssjukdom 2018 Indikatorer och underlag för bedömningar. Socialstyrelsen [www]. [updated 2018-01-01, cited 2022-01-22].

  2. Subramaniapillai S, Almey A, Natasha Rajah M, Einstein G. Sex and gender differences in cognitive and brain reserve: Implications for Alzheimer's disease in women. Front Neuroendocrinol. 2021;60:100879.

  3. Niu H, Álvarez-Álvarez I, Guillén-Grima F, Aguinaga-Ontoso I. Prevalence and incidence of Alzheimer's disease in Europe: A meta-analysis. Neurologia. 2017;32(8):523-532.

  4. Assessment report - Leqembi (lecanemab). European Medicines Agency (EMA) [www]. [updated 2024-11-14, cited 2025-09-29].

  5. Teipel SJ, Tang Y, Khachaturian A. Sex differences in treatment effects of lecanemab and donanemab: A Bayesian reanalysis of CLARITY-AD and TRAILBLAZER-ALZ2. Alzheimers Dement (N Y). 2025;11(3):e70155.

  6. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21.

  7. Food and Drug Administration (FDA). Drug label - Leqembi (lecanemab). Drugs@FDA [www]. [updated 2025-08-01, cited 2025-10-01].

  8. Andrews D, Ducharme S, Chertkow H, Sormani MP, Collins DL, Alzheimer's Disease Neuroimaging Initiative. The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect. Alzheimers Dement. 2025;21(1):e14467.

  9. Kong L, Yang X, Xu J. Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system. Front Pharmacol. 2025;16:1593989.

  1. Nationella riktlinjer – Utvärdering 2018 Vård och omsorg vid demenssjukdom 2018 Indikatorer och underlag för bedömningar. Socialstyrelsen [www]. [updated 2018-01-01, cited 2022-01-22].
  2. Subramaniapillai S, Almey A, Natasha Rajah M, Einstein G. Sex and gender differences in cognitive and brain reserve: Implications for Alzheimer's disease in women. Front Neuroendocrinol. 2021;60:100879.
  3. Niu H, Álvarez-Álvarez I, Guillén-Grima F, Aguinaga-Ontoso I. Prevalence and incidence of Alzheimer's disease in Europe: A meta-analysis. Neurologia. 2017;32(8):523-532.
  4. Assessment report - Leqembi (lecanemab). European Medicines Agency (EMA) [www]. [updated 2024-11-14, cited 2025-09-29].
  5. Teipel SJ, Tang Y, Khachaturian A. Sex differences in treatment effects of lecanemab and donanemab: A Bayesian reanalysis of CLARITY-AD and TRAILBLAZER-ALZ2. Alzheimers Dement (N Y). 2025;11(3):e70155.
  6. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21.
  7. Food and Drug Administration (FDA). Drug label - Leqembi (lecanemab). Drugs@FDA [www]. [updated 2025-08-01, cited 2025-10-01].
  8. Andrews D, Ducharme S, Chertkow H, Sormani MP, Collins DL, Alzheimer's Disease Neuroimaging Initiative. The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect. Alzheimers Dement. 2025;21(1):e14467.
  9. Kong L, Yang X, Xu J. Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system. Front Pharmacol. 2025;16:1593989.